| Feature Type | Standardized | Nominal ANOVA | ||||
|---|---|---|---|---|---|---|
| mRNA | Doxorubicin | FIMM | pan-cancer | AAC | -0.025 | 0.9 |
| mRNA | XMD15-27 | GDSC1000 | pan-cancer | AAC | -0.0056 | 0.9 |
| mRNA | BRD-K34485477 | CTRPv2 | pan-cancer | AAC | -0.012 | 0.9 |
| mRNA | BRD-A02303741:carboplatin (1:1 mol/mol) | CTRPv2 | pan-cancer | AAC | -0.0058 | 0.9 |
| mRNA | Gefitinib | FIMM | pan-cancer | AAC | -0.026 | 0.9 |
| mRNA | Panobinostat | FIMM | pan-cancer | AAC | -0.017 | 0.9 |
| mRNA | GW843682X | GDSC1000 | pan-cancer | AAC | -0.0072 | 0.9 |
| mRNA | cyanoquinoline 11 | CTRPv2 | pan-cancer | AAC | -0.0067 | 0.9 |
| mRNA | NPC-26 | CTRPv2 | pan-cancer | AAC | -0.0047 | 0.9 |
| mRNA | Vandetanib | CTRPv2 | pan-cancer | AAC | -0.0041 | 0.9 |